Страна: Йордания
Език: английски
Източник: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Erythropoietin Alfa 5000 IU/0.5ml
مستودع ادوية شاوي و رشيدات و مسنات - Shawi & Rushedat Drug Store
B03XA01
Erythropoietin Alfa 5000 IU/0.5ml
5000 IU/0.5ml
6PFS X 0.5ml
فيتير فارما (المانيا)
PRODUCT NAME EPREX ® (Epoetinum alfa) Pre-filled Syringe DOSAGE FORMS AND STRENGTHS Epoetinum alfa, a glycoprotein produced by recombinant DNA technology, is the active ingredient. Epoetinum alfa is a sterile, clear, colorless, buffered parenteral solution for intravenous or subcutaneous injection. EPOETINUM ALFA IN PRE-FILLED SYRINGES WITH NEEDLE GUARD (PROTECS ™ ) Concentration of Epoetinum alfa g Volume per syringe (mL) International Units 1000 8.4 0.5 2000 16.8 0.5 3000 25.2 0.3 4000 33.6 0.4 5000 42.0 0.5 6000 50.4 0.6 8000 67.2 0.8 10000 84.0 1.0 20000 168.0 0.5 30000 252 0.75 40000 336.0 1.0 For excipients, see _List of Excipients_. CLINICAL INFORMATION INDICATIONS EPREX ® is indicated for the treatment of anemia associated with chronic renal failure in adult patients on hemodialysis and peritoneal dialysis, and in pediatric patients on hemodialysis. EPREX ® is indicated for the treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. EPREX ® is indicated for the treatment of anemia and reduction of transfusion requirements in adult cancer patients with non-myeloid malignancies receiving chemotherapy. EPREX ® is indicated for the treatment of anemia in adult HIV infected patients being treated with zidovudine having endogenous erythropoietin levels ≤ 500 mU/mL. EPREX ® is indicated in adults to facilitate autologous blood collection within a predeposit program and decrease the risk of receiving allogeneic blood transfusions in patients with moderate anemia (hematocrits of 33-39%, hemoglobin of 10-13 g/dL, [6.2-8.1 mmol/L], no iron deficiency), who are scheduled for major elective surgery and are expected to require more blood than that which can be obtained through autologous blood collection techniques in the absence of EPREX ® . Treatment should only be given to patients if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of b Прочетете целия документ